Main Uses of Flotral-D

Flotral-D is a combination medication primarily used for the treatment of Benign Prostatic Hyperplasia (BPH), a condition characterized by an enlarged prostate gland in men. It is designed to manage the functional and structural aspects of the condition simultaneously.

Primary Indications

• Relief of Urinary Symptoms: The medication helps alleviate lower urinary tract symptoms (LUTS) associated with an enlarged prostate, such as difficulty starting urination, a weak stream, and the sensation that the bladder is not completely empty.
• Reduction of Urinary Urgency and Frequency: It is used to decrease the frequent need to urinate, including nocturia (waking up multiple times during the night to urinate).
• Prevention of Disease Progression: The treatment aims to reduce the long-term risk of complications associated with BPH, such as acute urinary retention or the eventual need for surgical intervention.

Benefits of Combined Therapy

Flotral-D integrates two different mechanisms of action to provide comprehensive management of BPH symptoms:

Immediate Symptom Management

One component of the medication works by relaxing the smooth muscles in the prostate and the bladder neck. This reduction in muscle tension lowers the resistance to urine flow, providing relatively rapid relief from obstructive symptoms.

Long-term Prostate Volume Reduction

The second component addresses the underlying cause of the symptoms by inhibiting the hormonal processes responsible for prostate growth. Over time, this helps to shrink the enlarged prostate gland, improving the physical passage of urine and stabilizing the condition.

Improved Quality of Life

By addressing both the immediate discomfort and the physical size of the prostate, the medication helps patients maintain better bladder control and reduces the disruptions to daily activities and sleep patterns caused by urinary symptoms.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Flotral-D?

This section outlines the officially documented population eligibility and non-eligibility rules for Flotral-D (Alfuzosin/Dutasteride), based strictly on government regulatory documents.

---

Contraindicated Populations

Flotral-D is absolutely contraindicated and must not be used by the following groups:

• Women who are pregnant or who may become pregnant (due to the risk of fetal harm from Dutasteride).
• Pediatric patients (children and adolescents), as the medicine is not indicated for this age group.
• Patients with moderate or severe hepatic impairment (liver dysfunction).
• Individuals with known hypersensitivity to the active ingredients or other 5α-reductase inhibitors.
• Patients concurrently taking potent CYP3A4 inhibitors or other alpha-adrenergic antagonists (alpha-blockers).

---

Eligibility and Restriction Rules

• Approved Population: Use is restricted to adult men with symptomatic benign prostatic hyperplasia (BPH).
• Organ Function: Use with caution is advised for patients with severe renal impairment or mild hepatic impairment.
• Comorbidities: Caution is required for patients with a history of hypotension or certain cardiac conditions (e.g., QT prolongation). Prostate carcinoma must be ruled out before initiating treatment.
• Geriatric Use: Use in older adults is generally acceptable, though caution is advised due to potential increased sensitivity.

Flotral-D (containing tamsulosin and dutasteride) can interact with a range of other medications, potentially increasing the risk of adverse effects, particularly low blood pressure. Always inform your healthcare provider about all prescription and non-prescription medicines, vitamins, and herbal supplements you are currently taking.

Medications to Avoid or Use with Caution

Interaction Type	Examples of Interacting Medicines	Potential Effect
Other Alpha-Blockers	Prazosin, Doxazosin, Alfuzosin, Silodosin	Significantly increased risk of hypotension (very low blood pressure) and fainting. This combination is generally contraindicated.
PDE-5 Inhibitors	Sildenafil, Tadalafil, Vardenafil (for Erectile Dysfunction)	Additive blood pressure-lowering effect, leading to a risk of symptomatic hypotension and dizziness.
CYP3A4 Inhibitors	Ketoconazole, Itraconazole, Ritonavir	Increase in Tamsulosin levels in the bloodstream, raising the risk of side effects, including low blood pressure.
CYP2D6 Inhibitors	Paroxetine	May increase Tamsulosin exposure, leading to an increased risk of side effects.
Warfarin (Anticoagulant)	Warfarin	Tamsulosin may interact with Warfarin, requiring careful monitoring of blood clotting and possible dose adjustment.

Other Important Interactions

• Alcohol: Consumption of alcohol may increase the risk of dizziness and low blood pressure when taking this medicine.
• Grapefruit: Large amounts of grapefruit or grapefruit juice may increase the risk of Tamsulosin-related side effects.

Never start or stop any medication without first consulting your doctor. Your healthcare team may adjust the dosage of your medications or increase monitoring to manage potential interactions.

How Flotral-D Works

The mechanism of Flotral-D is based on a complementary dual action, simultaneously modulating two distinct physiological domains: smooth muscle tension and tissue growth signaling.

---

⌢️ Modulating Smooth Muscle Tension via alpha1-Receptor Blockade

This domain describes the action kinetics of Alfuzosin, which acts as a selective antagonist of the alpha1-adrenoreceptors in the lower urinary tract smooth muscle. By blocking these receptors, the drug suppresses norepinephrine-mediated contraction, resulting in the relaxation of smooth muscle within the prostatic stroma and bladder neck. This physiological change reduces tension and resistance, resulting in a decrease in resistance at the bladder outlet.

---

↗️ Inhibiting Androgen-Driven Tissue Growth

This domain covers the long-term, structural mechanism of Dutasteride, which functions as a dual inhibitor of the Type 1 and Type 2 5alpha-reductase enzyme. This enzyme inhibition drastically lowers the concentration of the growth-stimulating hormone, Dihydrotestosterone (DHT), within the prostate. The resulting loss of the DHT trophic signal induces epithelial apoptosis and decreases cell mass, resulting in a change in prostatic tissue size.

The administration of Flotral-D involves specific protocols to ensure consistent delivery of its components, Alfuzosin (10 mg) and Dutasteride (0.5 mg). The following outlines the usage protocol and the standard administration requirements.

Administration Protocol

The standard regimen for adult use is one tablet taken once daily. This fixed dosage schedule is intended to be maintained consistently over the entire course of treatment.

Administration Requirement	Requirement Detail
Route of Administration	Oral via tablet.
Timing with Meals	Must be taken immediately after the same meal each day.
Preparation	The tablet must be swallowed whole and must not be chewed, crushed, or opened.

Usage Patterns and Constraints

Flotral-D is intended for long-term management. The full response related to prostate volume reduction typically requires continuous treatment for up to six months.

The drug's administration carries specific constraints for certain patient populations. For instance, the use of Flotral-D is contraindicated in patients with moderate or severe hepatic impairment. No dosage adjustment is typically required for older adults.

If a daily dose is missed, the protocol is not to take an extra tablet to compensate. The usual schedule should be resumed by taking the next dose immediately after the regular daily meal. The necessity to take the tablet whole and with a meal is designed to protect the drug's modified-release properties and ensure proper systemic absorption.

Flotral-D: Recent Clinical Evidence

---

Evidence for Use in Benign Prostatic Hyperplasia (BPH) / LUTS

Research on Flotral-D, which combines the active ingredients Alfuzosin and Dutasteride, was primarily conducted using randomized controlled trials (RCTs). These studies were designed to explore how symptoms change over time in men diagnosed with an enlarged prostate, where studies evaluated symptom patterns associated with the condition. The studies monitored groups of patients who received the combination therapy, often comparing them to groups receiving a single ingredient or an inactive treatment (placebo).

Researchers examined several key outcomes related to functional imbalance and daily functioning. Primary assessments were based on measurements of the International Prostate Symptom Score (IPSS) and patient-reported outcomes describing perceived discomfort and quality of life. Studies also monitored objective measurements, such as the peak urinary flow rate ( Q max) and prostate volume measurements.

---

Understanding Long-Term Studies and Durability of Evidence

Longer-term research exploring extended periods of observation, with some follow-up durations extending up to two years, also exists. These extended studies applied observational settings evaluating daily-life functioning and collected data on patient-reported experiences over an intermediate period. The research explored the evolution of symptom patterns beyond the initial treatment phases.

Research available for extended periods of observation is limited, and the extent of long-term patterns remains less defined than the data collected during initial treatment phases. The available data describe patterns related to measurements collected over limited periods, and evidence for the full durability of observed symptom patterns beyond two years remains limited.

---

Evidence in Specific Groups of Patients

Flotral-D was evaluated in study populations composed of adult men, including geriatric populations (age 65 and up). Studies explored the use of the drug in certain groups with co-occurring conditions, like hypertension, when participants were receiving co-medication. However, data for certain specific groups remain insufficient, as patients with severe systemic impairment were typically excluded from the primary trials. Subgroup findings are uncertain for those with more complex or severe co-existing conditions.

---

What is Still Uncertain About the Research for Flotral-D

The research provides context about what has been observed so far, but several aspects remain uncertain. One of the primary research limitation frames is that comparative evidence against all alternative treatments is lacking. The certainty remains low regarding the types of outcomes measured in individuals with severe co-morbidities due to their exclusion from primary research settings. More research is ongoing to expand the broader evidence landscape related to extended observation.

Key Studies & References

1. A Randomized, Double-blind, Parallel Group Study to Investigate the Efficacy and Safety of Treatment With Dutasteride (0.5mg) and Tamsulosin (0.4mg), Administered Once Daily for 4 Years, Alone and Combination, on the Improvement of Symptoms and Clinical Outcome in Men With Moderate to Severe Symptomatic Benign Prostatic Hyperplasia (CombAT Trial)
2. Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use (Observational Study)

Flotral-D (Alfuzosin and Dutasteride) Storage and Disposal

The medicine must be stored at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F), and must be kept in its original container.

Required Handling and Safety

Requirement	Instruction
Child Safety	Must be kept out of the sight and reach of children.
Special Handling	Women who are pregnant or may become pregnant must not handle the capsules due to the risk of dermal absorption.
Disposal	Do not flush down the toilet. Dispose of via a drug take-back program or by mixing with an undesirable substance (e.g., dirt) in a sealed bag before discarding in the trash.

Storage outside of the allowed temperature limits is prohibited to maintain product stability. Contact with a broken capsule requires immediate washing of the exposed area with soap and water.